TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6339349
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml HBIG at birth, 3 months, and 6 months
Study: 6339349
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml HBIG at birth only
Study: 31504693
Drug: Daytime protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime protein (30 g casein) 30 min post-resistance exercise
Study: 31504693
Drug: Presleep placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presleep placebo (0 g casein) 30 min before bed
Study: 28587789
Drug: Once-weekly albiglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly albiglutide
Study: 14981370
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives with desogestrel (DG/EE)
Study: 14981370
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives with levonorgestrel (LNG/EE)
Study: 14981370
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives with both preparations (LNG/EE and DG/EE)
Study: 11712093
Drug: Re-treatment with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-treatment with artemisinin
Study: 11712093
Drug: Artemisinin treatment
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin treatment
Study: 9151026
Drug: Heparin treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin treated circuits (Duraflo II)
Study: 7951083
Drug: Berodual (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berodual (1 dose = 0.02 mg ipratropium bromide + 0.05 mg fenoterol), administered 3 x 1 dose/daily for 14 days
Study: 7951083
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (Atrovent, 1 dose = 0.02 mg), administered 3 x 2 doses/daily for 14 days
Study: 7951083
Drug: Fenoterol (Berotec,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (Berotec, 1 dose = 0.2 mg), administered 3 x 2 doses/daily for 14 days
Study: 29303771
Drug: Medium-term biological
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-term biological variation assessment (blood sampling once/week for five consecutive weeks)
Study: 29303771
Drug: Short-term biological
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term biological variation assessment (blood sampling once/day for five consecutive days)
Study: 17217716
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion (10 microg kg‐1 min‐1, increasing to 40 microg kg‐1 min‐1 at 3 min intervals)
Study: 14594938
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HF group), fraction size 1.2 Gy, mean total dose 73.4 Gy (range, 66-79.2 Gy)
Study: 14594938
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HF group)
Study: 14594938
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiation therapy (CF group), fraction size 1.8-2.0 Gy, mean total dose 65.4 Gy (range, 60-70 Gy)
Study: 14594938
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiation therapy (CF group)
Study: 7901585
Drug: Albendazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (10 mg/kg daily) for 1 month (group A)
Study: 7901585
Drug: Albendazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (10 mg/kg daily) for about 3 months (group B)
Study: 2939116
Drug: etodolac 50‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac 50‐600 mg/d
Study: 25085036
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 mg/kg bolus)
Study: 17993823
Drug: Daily-wear basis
Normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily-wear basis
Study: 16385384
Drug: s.c. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. infusion of saline (SAL)
Study: 16385384
Drug: s.c. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. infusion of GLP‐1 (2.4 pmol kg(‐1) min(‐1); LSC)
Study: 16385384
Drug: s.c. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. infusion of GLP‐1 (2.4 pmol kg(‐1) min(‐1)) in combination with a DPP‐4 inhibitor (IB)
Study: 16385384
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of GLP‐1 (1.2 pmol kg(‐1) min(‐1); IV)
Study: 16385384
Drug: s.c. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. infusion of GLP‐1 (9.6 pmol kg(‐1) min(‐1); HSC)
Study: 1633753
Drug: Triazolam (0.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.32 mg/70 kg)
Study: 1633753
Drug: Triazolam (0.1‐0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.1‐0.75 mg/70 kg)
Study: 6241386
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (group II)
Study: 6241386
Drug: Total coronary
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total coronary occlusion treatment
Study: 30202408
Drug: Gross myofascial
Normalized name: Ostericum grosseserratum root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gross myofascial release (MFR) of neck and upper limb in addition to conventional therapy (hot moist pack, TENS, stretching and strengthening exercises) for 6 consecutive days.
Study: 30202408
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (hot moist pack, TENS, stretching and strengthening exercises) for 6 consecutive days.
Study: 21320855
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume feeds at 300 ml/kg/day
Study: 21320855
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume feeds at 200 ml/kg/day
Study: 20561621
Drug: Standard-volume PEG-electrolyte
Normalized name: ELECTROLYTES/PEG-3350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-volume PEG-electrolyte solution
Study: 20561621
Drug: Split-dosage regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dosage regimen
Study: 20561621
Drug: Fair/poor preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fair/poor preparation
Study: 20561621
Drug: Non-split-dosage arm
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-split-dosage arm
Study: 20561621
Drug: Non-split-dosage bowel
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-split-dosage bowel preparation schedule
Study: 17439381
Drug: TLC diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC diet plus soy nuts (25 g soy protein and 101 mg aglycone isoflavones)
Study: 8820174
Drug: Apomorphine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (0.5 mg sc)
Study: 30260273
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg) administered via intravenous infusion
Study: 26840331
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 mg/day)
Study: 23619342
Drug: Se‐75‐homocholic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se‐75‐homocholic acid taurine (Se‐75‐HCAT) administered orally
Study: 20350153
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) as a full-mouth procedure after scaling and root planing (SRP)
Study: 20350153
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with photosensitizer solution without laser irradiation
Study: 19052402
Drug: Azathioprine 100
Normalized name: azathioprine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 100 mg daily (group A)
Study: 19052402
Drug: Betamethasone 2
Normalized name: betamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 2 mg daily (group B)
Study: 15876902
Drug: Citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 40 mg/d
Study: 10380021
Drug: Intravenous 500
Normalized name: Cytovene-IV 500 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 500 mg acetazolamide (Diamox) (Group 1)
Study: 1998656
Drug: niacin/colestipol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin/colestipol therapy
Study: 30089614
Drug: Highest oxLDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest oxLDL quartile (≥28.81 μg/dL)
Study: 24999157
Drug: Combined albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined albendazole (15 mg/kg per day) plus praziquantel (50 mg/kg per day)
Study: 24999157
Drug: Standard albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard albendazole (15 mg/kg per day)
Study: 24999157
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose albendazole (22.5 mg/kg per day)
Study: 22553354
Drug: Betulinic acid
Normalized name: Betulinic Acid
DrugBank: Betulinic Acid (DB12480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betulinic acid (1 to 10 μmol/L)
Study: 16088266
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment and repeated thermal therapy (far-infrared ray dry sauna therapy and post-sauna warming, once a day for 4 weeks)
Study: 16088266
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment (cognitive behavioral therapy, rehabilitation, and exercise therapy)
Study: 12805913
Drug: Lidocaine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (600 mg + 5 mg/ml adrenaline)
Study: 12805913
Drug: Mepivacaine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine (600 mg + 5 microg/ml adrenaline)
Study: 9505892
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose enteric coated pancreatin enzyme supplementation
Study: 2128929
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation (CP)
Study: 2128929
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation (CP) with Sennosides
Study: 2128929
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy utilizing Metronidazole
Study: 2128929
Drug: 24-hour antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour antibiotic therapy utilizing Metronidazole (1.5 g) and/or Cefotaxime (4 g)
Study: 75643
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of any two diagnostic methods
Study: 19884554
Drug: Model for
Normalized name: Model AA 2012 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model for response prediction including RRM1, ERCC1, and treatment arm
Study: 17084905
Drug: Family-focused psychoeducation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused psychoeducation and pharmacotherapy
Study: 8240465
Drug: ibuprofen/placebo (stomach)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen/placebo (stomach) 0.9 ± 0.1
Study: 8240465
Drug: ibuprofen/placebo (duodenum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen/placebo (duodenum) 0.0 ± 0.0
Study: 8240465
Drug: ibuprofen/ranitidine (stomach)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen/ranitidine (stomach) 0.8 ± 0.1
Study: 8240465
Drug: ibuprofen/ranitidine (duodenum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen/ranitidine (duodenum) 0.1 ± 0.1
Study: 8240465
Drug: ibuprofen/placebo (duodenum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen/placebo (duodenum) 0.2 ± 0.1
Study: 8240465
Drug: ibuprofen/ranitidine (stomach)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen/ranitidine (stomach) 0.9 ± 0.1
Study: 31548130
Drug: Initial mpMRI
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial mpMRI followed by biopsy for negative mpMRI (PI-RADS 1-2) if the 4Kscore was >18% or PSAd was >0.10ng/ml/cm3
Study: 31548130
Drug: PSAd <0.10ng/ml/cm3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSAd <0.10ng/ml/cm3
Study: 17007757
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid group (prednisolone 2mg/kg/day on alternate days, tapered over 8 weeks)
Study: 17007757
Drug: Intra-lesional steroid
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-lesional steroid group (triamcinolone 1 to 5 mg/kg, max 30mg, six injections monthly)
Study: 17007757
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid group
Study: 17007757
Drug: Intra-lesional steroid
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-lesional steroid group
Study: 9399753
Drug: 6-mercaptopurine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mercaptopurine (50 mg daily)
Study: 15362027
Drug: mesalamine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalamine (3 g daily)
Study: 11493295
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel dressings
Study: 11493295
Drug: Nonsilicone gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsilicone gel dressings
Study: 2884811
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg/day)
Study: 31771385
Drug: B+P (biological
Approvals — FDA: no, EMA: no, PMDA: no
Description: B+P (biological management with prevention)
Study: 23880195
Drug: Pravastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin therapy for 2 years
Study: 21071361
Drug: O+O (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: O+O (oral stimulation)
Study: 17010806
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy with elastic bandage of the legs (compression pressure 40 to 60 mm Hg) and abdomen (compression pressure 20 to 30 mm Hg) for 10 min each.
Study: 17010806
Drug: Therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with elastic compression stockings of the legs (prescribed in all patients).
Study: 9826312
Drug: Bosentan (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (1.0 g BID)
Study: 1084825
Drug: Sulindac 240
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac 240 mg
Study: 1084825
Drug: Sulindac 400
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac 400 mg
Study: 1084825
Drug: Aspirin 4.8
Normalized name: oxycodone HCl/aspirin 4.8355 mg-325 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 4.8 gm
Study: 31222344
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Mo and Cd co-treated group
Study: 31222344
Drug: Combination groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination groups (Mo and Cd co-exposure)
Study: 21555773
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg of teriparatide once daily for 28 days
Study: 19555809
Drug: L-arginine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (1.5 g bid)
Study: 19555809
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg qd) with L-arginine
Study: 17200474
Drug: Pexelizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pexelizumab (2 mg/kg intravenous bolus prior to PCI followed by 0.05 mg/kg per hour infusion over 24 hours)
Study: 11453960
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone (5 or 10 mg)
Study: 7912766
Drug: Virosome influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosome influenza vaccine
Study: 7912766
Drug: Commercial whole-virus
Normalized name: INFLUENZA A VIRUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial whole-virus vaccine
Study: 2073959
Drug: Krill enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill enzyme treatment
Study: 2073959
Drug: Non-enzymatic treatment
Normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-enzymatic treatment
Study: 781227
Drug: Fenoprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoprofen (400 mg Q6H)
Study: 781227
Drug: Aspirin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1,000 mg Q6H)
Study: 31562758
Drug: Maintenance olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance olaparib (300 mg b.i.d.; tablets)
Study: 28558366
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment in MDD patients with AIHM
Study: 26091286
Drug: BR-TD-1001 (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: BR-TD-1001 (test vaccine)
Study: 19449015
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy for slow-transit constipation
Study: 16413699
Drug: Preradiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preradiotherapy treatment
Study: 16413699
Drug: Postradiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postradiotherapy treatment
Study: 16413699
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with major deviations in treatment schedule
Study: 16413699
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without major deviations in treatment schedule
Study: 16608381
Drug: Intravenous propionyl
Normalized name: 3-Propionyl-10-dimethylaminoisopropylphenothiazine
DrugBank: Propiomazine (DB00777)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propionyl L‐carnitine 600 mg 3 times weekly for 12 months
Study: 7734254
Drug: Hyperbaric amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric amethocaine 8 mg
Study: 2271747
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg SR tablets after a high fat breakfast
Study: 2271747
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg SR tablets in fasted state
Study: 2271747
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg SR tablets 1 h before, 0.5 h after, 2 h after a high fat meal
Study: 31182442
Drug: Prescription support-tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription support-tool
Study: 31182442
Drug: No prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prescription support-tool (Control)
Study: 23599316
Drug: RRV-TV (tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV-TV (tetravalent rotavirus vaccine)
Study: 19660042
Drug: Abstinence with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence with transdermal nicotine patch
Study: 14756910
Drug: Cream (CREAM)
Normalized name: Oral Cream
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream (CREAM)
Study: 3795326
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with mebendazole (1800 mg day-1 for 18 weeks)
Study: 3795326
Drug: Interrupted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted therapy with mebendazole (1800 mg day-1 for interrupted 6-week courses for a minimum of three courses, with intervals of 19-22 weeks)
Study: 29648532
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) tablet of repaglinide/metformin (2/500 mg)
Study: 29648532
Drug: Equivalent doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent doses of individual (EDI) tablets of repaglinide (2 mg) and metformin (500 mg)
Study: 26431653
Drug: Chinese drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drug iontophoresis
Study: 21477901
Drug: Sterol fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterol fortified orange juice (1g/240 ml juice twice a day)
Study: 21477901
Drug: Sterol fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterol fortified OJBev (1g/240 ml beverage twice a day)
Study: 15614460
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg ivermectin (110 microg/kg) administered as a single dose, repeated 2 weeks later
Study: 15614460
Drug: 200 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg/kg ivermectin administered as a single dose, repeated 2 weeks later
Study: 12032393
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of 8000 anti-FXa units LMWH Certoparin
Study: 12032393
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 8000 anti-FXa units LMWH Certoparin
Study: 785948
Drug: Haloperidol administered
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol administered for 16 weeks
Study: 30611454
Drug: PFMT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFMT plus solifenacin (5 mg/d over 36 weeks)